These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15848680

  • 1. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Joh JW, Lee HH, Park JW, Lee DH, Yoo BC, Lee KW, Kim SJ.
    Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
    [Abstract] [Full Text] [Related]

  • 2. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ.
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [Abstract] [Full Text] [Related]

  • 3. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H.
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [Abstract] [Full Text] [Related]

  • 4. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R.
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [Abstract] [Full Text] [Related]

  • 5. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, Kim SJ, Joh JW, Oh HY.
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [Abstract] [Full Text] [Related]

  • 6. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [Abstract] [Full Text] [Related]

  • 7. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX, Li J, Qiu LM, Luo YW, Chen YH, Ran Y.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [Abstract] [Full Text] [Related]

  • 8. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R, Kumashiro R, Murashima S, Ogata K, Tanaka K, Hisamochi A, Hino T, Ide T, Tanaka E, Koga Y, Sata M.
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [Abstract] [Full Text] [Related]

  • 9. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 11. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Nov; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 12. HBV resistant to lamivudine: experimental and clinical studies.
    Zhou DY, Cao YJ, Lin LY, Wang H, Huang JS.
    Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):519-22. PubMed ID: 14607678
    [Abstract] [Full Text] [Related]

  • 13. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG, Song E, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [Abstract] [Full Text] [Related]

  • 14. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [Abstract] [Full Text] [Related]

  • 15. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM.
    Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
    [Abstract] [Full Text] [Related]

  • 16. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [Abstract] [Full Text] [Related]

  • 17. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 Oct; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 18. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B, Wei L, Chen M, Wang L.
    Microbiol Res; 2008 Oct; 163(4):487-92. PubMed ID: 17317127
    [Abstract] [Full Text] [Related]

  • 19. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 20. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.